Ablynx NV has appointed Debbie Law, a biotechnology industry veteran, as its chief scientific officer. Previously, Dr Law was vice president of research at PDL BioPharma and before that, held senior research positions with EOS Biotechnology and COR Therapeutics, all of the US. Dr Law received a D. Phil in immunology from the University of Oxford in 1989. At Ablynx she will head up research activities and identify and prioritise new therapeutic programmes.
Dr Law succeeds Hennie Hoogenboom who stepped down as CSO in April 2008.
Copyright 2009 Evernow Publishing Ltd